摘要
患者对药物反应的个体差异,一般是由药物在体内的代谢酶、转运体和靶点编码基因的多态性引起的。因为免疫抑制剂的治疗窗口较窄,患者个体差异导致的不良反应和疗效不佳,都可能引起比较严重的后果,近年人们对于利用药物基因组学进行个体化治疗给予了很高的期待。大量研究已经揭示了多种基因多态性与免疫抑制剂的药代动力学和药效动力学(PK/PD)之间的关联。本文将围绕免疫抑制剂的PK/PD,选择部分具备临床参考意义的研究,简要综述与免疫抑制剂代谢、转运和活化过程相关的药物基因组学进展。
The individual differences in the patients′ response to the drug are generally caused by polymorphisms in the metabolic enzymes,transporters,and target- encoding genes of the drug in the body.The therapeutic window of immunosuppressive agents is narrow,and the adverse reactions and poor efficacy caused by individual differences in patients may cause serious consequences.In recent years,people have high expectations for individualized treatment using pharmacogenomics.Numerous studies have revealed a link between multiple gene polymorphisms and pharmacokinetics and pharmacodynamics(PK/PD)of immunosuppressive agents.This review focused on the PK/PD of immunosuppressants in some selected studies with clinical significance to briefly review the progress of pharmacogenomics related to the process of metabolism,transport,and activation of immunosuppressants.
作者
范皎
胡梦
陈香岭
万军
张明华
Fan Jiao;Hu Meng;Chen Xiangling;Wan Jun;Zhang Minghua(PLA General Hospital,Beijing 100853,China;Clinical Pharmacy Laboratory;Department of South Building Gastroenterology)
出处
《中华肾病研究电子杂志》
2018年第6期280-284,共5页
Chinese Journal of Kidney Disease Investigation（Electronic Edition）
基金
国家卫计委保健重点科研项目(W2016ZD02)
